IL111978A - Dry-compressed paroxetine formulations - Google Patents

Dry-compressed paroxetine formulations

Info

Publication number
IL111978A
IL111978A IL11197894A IL11197894A IL111978A IL 111978 A IL111978 A IL 111978A IL 11197894 A IL11197894 A IL 11197894A IL 11197894 A IL11197894 A IL 11197894A IL 111978 A IL111978 A IL 111978A
Authority
IL
Israel
Prior art keywords
dry
formulations
compressed
compressed paroxetine
paroxetine formulations
Prior art date
Application number
IL11197894A
Other languages
English (en)
Other versions
IL111978A0 (en
Original Assignee
Smithkline Beecham Corporate I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10746644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL111978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporate I filed Critical Smithkline Beecham Corporate I
Publication of IL111978A0 publication Critical patent/IL111978A0/xx
Publication of IL111978A publication Critical patent/IL111978A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11197894A 1993-12-15 1994-12-14 Dry-compressed paroxetine formulations IL111978A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939325644A GB9325644D0 (en) 1993-12-15 1993-12-15 Novel formulation

Publications (2)

Publication Number Publication Date
IL111978A0 IL111978A0 (en) 1995-03-15
IL111978A true IL111978A (en) 2000-07-16

Family

ID=10746644

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11197894A IL111978A (en) 1993-12-15 1994-12-14 Dry-compressed paroxetine formulations

Country Status (36)

Country Link
US (1) US6113944A (xx)
EP (1) EP0734260B2 (xx)
JP (1) JP3037757B2 (xx)
KR (1) KR100367796B1 (xx)
CN (1) CN1071116C (xx)
AP (1) AP540A (xx)
AT (1) ATE180973T1 (xx)
AU (1) AU697982B2 (xx)
BG (1) BG62755B1 (xx)
BR (1) BR9408219A (xx)
CA (4) CA2178637C (xx)
CZ (1) CZ287891B6 (xx)
DE (1) DE69419033T2 (xx)
DK (1) DK0734260T4 (xx)
DZ (1) DZ1835A1 (xx)
ES (1) ES2132610T5 (xx)
FI (1) FI962445A (xx)
GB (1) GB9325644D0 (xx)
GR (1) GR3031047T3 (xx)
HK (1) HK1012285A1 (xx)
HU (1) HUT75880A (xx)
IL (1) IL111978A (xx)
MA (1) MA23395A1 (xx)
MY (1) MY112123A (xx)
NO (1) NO307366B1 (xx)
NZ (1) NZ277790A (xx)
OA (1) OA10297A (xx)
PL (1) PL314980A1 (xx)
RO (1) RO115413B1 (xx)
RU (1) RU2146141C1 (xx)
SA (1) SA94150373B1 (xx)
SI (1) SI0734260T2 (xx)
SK (1) SK282620B6 (xx)
UA (1) UA42745C2 (xx)
WO (1) WO1995016448A1 (xx)
ZA (1) ZA949900B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5874447A (en) 1997-06-10 1999-02-23 Synthon B. V. 4-Phenylpiperidine compounds for treating depression
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
GB9810181D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulations
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
UA79930C2 (en) 2001-07-31 2007-08-10 Lundbeck & Co As H Crystalline composition containing escitalopram
HUP0401895A2 (hu) * 2001-10-22 2004-12-28 Synthon B.V. Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL162458A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
CN1997374A (zh) * 2004-06-23 2007-07-11 默克公司 雌激素受体调节剂
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN109771381B (zh) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 一种帕罗西汀药物制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50116401A (xx) * 1974-03-04 1975-09-11
ZA813205B (en) † 1980-12-05 1983-03-30 Smith Kline French Lab Dosage units
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
SI0734260T2 (sl) 2008-12-31
IL111978A0 (en) 1995-03-15
BG62755B1 (bg) 2000-07-31
HUT75880A (en) 1997-05-28
US6113944A (en) 2000-09-05
JPH09506602A (ja) 1997-06-30
NZ277790A (en) 1998-02-26
NO962547L (no) 1996-06-14
BR9408219A (pt) 1997-08-26
CN1137236A (zh) 1996-12-04
CA2274389C (en) 2004-09-14
CA2178637A1 (en) 1995-06-22
EP0734260A1 (en) 1996-10-02
EP0734260B2 (en) 2008-07-09
CZ176396A3 (en) 1996-09-11
WO1995016448A1 (en) 1995-06-22
KR100367796B1 (ko) 2003-07-22
ES2132610T5 (es) 2008-12-16
PL314980A1 (en) 1996-09-30
DZ1835A1 (fr) 2002-02-17
DK0734260T3 (da) 1999-11-15
ZA949900B (en) 1995-10-10
NO307366B1 (no) 2000-03-27
NO962547D0 (no) 1996-06-14
EP0734260B1 (en) 1999-06-09
MY112123A (en) 2001-04-30
SA94150373B1 (ar) 2006-05-27
MA23395A1 (fr) 1995-07-01
HK1012285A1 (en) 1999-07-30
SK282620B6 (sk) 2002-10-08
CA2178637C (en) 1997-12-23
AU697982B2 (en) 1998-10-22
CA2214575C (en) 1999-12-07
HU9601665D0 (en) 1996-08-28
CA2274387A1 (en) 1995-06-22
ATE180973T1 (de) 1999-06-15
GB9325644D0 (en) 1994-02-16
ES2132610T3 (es) 1999-08-16
AP540A (en) 1996-09-20
UA42745C2 (uk) 2001-11-15
DE69419033T2 (de) 1999-11-25
AP9400704A0 (en) 1995-01-31
SA94150373A (ar) 2005-12-03
CA2274389A1 (en) 1995-06-22
SI0734260T1 (en) 1999-08-31
DE69419033D1 (de) 1999-07-15
RO115413B1 (ro) 2000-02-28
CN1071116C (zh) 2001-09-19
OA10297A (en) 1997-10-07
SK75696A3 (en) 1996-11-06
CA2214575A1 (en) 1995-06-22
GR3031047T3 (en) 1999-12-31
RU2146141C1 (ru) 2000-03-10
BG100648A (bg) 1997-02-28
DK0734260T4 (da) 2008-09-29
AU1314595A (en) 1995-07-03
FI962445A0 (fi) 1996-06-12
JP3037757B2 (ja) 2000-05-08
CZ287891B6 (cs) 2001-03-14
FI962445A (fi) 1996-06-12

Similar Documents

Publication Publication Date Title
IL111978A (en) Dry-compressed paroxetine formulations
IL109056A0 (en) Vaccine compositions
PL315128A1 (en) Anti-pollutant compositions
IL110665A0 (en) Erection-inducing compositions
EP0721328A4 (en) CAMPTOTHECIN FORMULATIONS
ZA945653B (en) Therapeutic compositions
ZA946195B (en) Anthelmintic formulations
GB9318641D0 (en) Compositions
GB9323313D0 (en) Clenasing compositions
GB9410252D0 (en) Galenic formulations
PL313979A1 (en) Vaccine composition
GB9304823D0 (en) Cable-making compositions
GB9326425D0 (en) Vaccine compositions
GB9306806D0 (en) Disinfectant compositions
GB9323270D0 (en) Disinfectant composition
GB9311030D0 (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9409835D0 (en) Compositions
GB9313759D0 (en) Cementiferous compositions
GB9308622D0 (en) Formulations
GB9306144D0 (en) Formulations
GB9324360D0 (en) Therapeutic compositions
GB9304797D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9314443D0 (en) Pharmaceutical formulations